Arteris Q3 Revenue Jumps 48% to $25.8M on AI Licensing Push

Arteris posted third-quarter revenue of $25.8 million, up 48 percent year over year, driven by AI-related licensing activity and its acquisition of Cycuity. The figure anchors what remains a divided story: strong top-line growth at a network-on-chip interconnect IP vendor whose cash generation and share dilution still worry investors.

What did the quarter deliver?

The revenue surge of 48 percent is the standout number. The analyst behind the coverage rates the stock a buy, with a fiscal 2027 price target of $23, which implies roughly 14 percent upside. That target comes after severe turbulence: the shares have suffered a 46 percent drawdown.

The growth engine is twofold. AI-related licensing demand lifted contract value, and the Cycuity acquisition added new business. Arteris sells network-on-chip interconnect intellectual property, the wiring fabric that links processor cores and memory blocks inside system-on-chip designs.

The takeaway: licensing demand is real and growing, but the market has already repriced the stock hard.

Why do chiplets matter to the story?

The forward-looking case rests on chiplets. Chiplet-based designs, where a system is split into multiple die packaged together, currently account for about 10 percent of all Arteris customer projects. The analyst expects that share to rise to between 30 and 35 percent.

That shift matters commercially because chiplet designs create royalty potential. Each interconnected die can carry per-unit payments rather than one-time license fees. If chiplet adoption accelerates as projected, royalties could compound on top of licensing revenue and reshape the company's growth profile.

The takeaway: the chiplet transition converts a license business into a recurring revenue business, which is the core of the bull case.

What still holds the company back?

Two weaknesses temper the growth story. Cash flow generation remains weak despite the revenue expansion. Share dilution also stays elevated, meaning existing holders keep absorbing new equity issuance.

The analyst flags a third concern: ACV plus royalties growth — the combined measure of annual contract value and per-unit payments — is decelerating rather than accelerating. The upside thesis depends on that metric speeding up, particularly as chiplet projects scale.

The takeaway: until cash flow strengthens and dilution shrinks, the market will treat the growth numbers with skepticism.

What kind of investment case is this?

The analyst describes Arteris as a "show-me" story after the correction. In plain terms, the company must demonstrate results before investors re-rate the stock.

The position of the analyst is disclosed as independent: no stock, option or derivative positions in the company, and no plans to initiate any within 72 hours. The article was written without compensation beyond the platform's payment.

The buy rating therefore rests on forward conviction, not on an existing stake.

What comes next?

The critical checkpoint is whether ACV plus royalties growth reaccelerates as chiplet designs climb from 10 percent toward the projected 30-35 percent of projects. If that shift materializes, royalties could redefine the growth story; if it stalls, the weak cash flow and elevated dilution will keep the multiple compressed.